Loading...
•
Mar 31, 2024
Johnson & Johnson Q1 2024 Earnings Report
Johnson & Johnson's first quarter performance in 2024 reflected a sharpened focus and progress in portfolio and pipeline.
Key Takeaways
Johnson & Johnson reported a solid first quarter in 2024, with sales growth of 2.3% to $21.4 billion and adjusted EPS growth of 12.4% to $2.71. The company is increasing its full-year 2024 operational sales and adjusted operational EPS guidance.
First-quarter sales grew by 2.3% to $21.4 billion, with operational growth of 3.9%.
Adjusted operational sales, excluding COVID-19 Vaccine, increased by 7.7%.
Earnings per share (EPS) increased to $2.20, and adjusted EPS increased to $2.71, a 12.4% increase.
The company is increasing the midpoint for full-year 2024 operational sales and adjusted operational EPS guidance.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson Revenue by Segment
Johnson & Johnson Revenue by Geographic Location
Revenue by Segment
Innovative Medicine Revenue
CapyFin.comMedTech Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Johnson & Johnson is increasing the midpoint for Full-Year 2024 operational sales and adjusted operational EPS guidance.
Positive Outlook
- Adjusted Operational Sales Change vs. Prior Year Mid-point: 5.8%
- Operational Sales Change vs. Prior Year Mid-point: 5.8%
- Estimated Reported Sales Change vs. Prior Year Mid-point: 5.0%
- Adjusted Operational EPS (Diluted) Change vs. Prior Year Mid-point: 7.7%
- Adjusted EPS (Diluted) Change vs. Prior Year Mid-point: 7.4%
Revenue & Expenses
Visualization of income flow from segment revenue to net income